Kiniksa insider Paolini exercises options at $3.80, sells at $32.55

Rhea-AI Filing Summary

John F. Paolini, Chief Medical Officer of Kiniksa Pharmaceuticals (KNSA), exercised 29,325 share options at an exercise price of $3.80 and sold 29,325 Class A Ordinary Shares at a weighted average price of $32.55 under a Rule 10b5-1 trading plan. The filing states the option is fully vested and exercisable and reports post-transaction beneficial ownership figures of 86,728 and 57,403 Class A shares, plus 36,542 derivative securities. The sale was executed through a broker-dealer in multiple trades and the filer offers to provide trade-level price details on request.

Positive

• Transaction executed under a Rule 10b5-1 plan, indicating a pre-established trading program
• Option is fully vested and exercisable, and the filer discloses willingness to provide detailed trade-level pricing

Negative

• Reported sale of 29,325 Class A Ordinary Shares, which reduces the reporting person’s beneficial ownership
• Post-transaction beneficial ownership figures include lower reported holdings (57,403 Class A shares) compared with pre-transaction totals

Insights

Securities Analyst

Routine option exercise and sale disclosed under a documented 10b5-1 plan; transparency is key for investors.

The filing shows an insider exercised 29,325 options at a low exercise price and sold the resulting shares at a materially higher weighted average price, producing potential cash proceeds. Because the transactions were processed under a Rule 10b5-1 plan and the option is confirmed fully vested, this appears to be a pre-planned, compliance-oriented disposition rather than an opportunistic market-timing sale. The filer’s offer to provide per-trade pricing supports transparency. Impact to outstanding float appears limited given the reported post-transaction ownership figures.

Corporate Governance Expert

Disclosure follows standard governance practices; documented plan and attorney-in-fact signature improve procedural clarity.

The Form 4 documents execution under a written 10b5-1 plan and includes an attorney-in-fact signature, which addresses procedural governance and insider-trading compliance considerations. The filing also discloses option vesting status and post-transaction ownership counts, enabling shareholders to assess insider alignment with company performance. While insider sales can raise investor questions, the presence of a pre-existing plan and explicit trade pricing information reduces ambiguity about intent.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Paolini John F.

(Last) (First) (Middle)

23 OLD BOND STREET, THIRD FLOOR

(Street)

LONDON X0 W1S 4PZ

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Share	08/06/2025		M(1)		29,325	A	$3.8	86,728	D
Class A Ordinary Share	08/06/2025		S(1)		29,325	D	$32.55(2)	57,403	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option	$3.8	08/06/2025		M(1)			29,325	(3)	06/28/2027	Class A Ordinary Share	29,325	$0	36,542	D

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2024.

2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $32.13 and $33.08. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

3. The option is fully vested and exercisable.

	/s/ Madelyn Zeylikman, Attorney-in-Fact	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for Kiniksa (KNSA)?

John F. Paolini, the company’s Chief Medical Officer, filed the Form 4 via an attorney-in-fact.

What transactions did the insider report on the Form 4 for KNSA?

Exercise of 29,325 share options at an exercise price of $3.80 and the sale of 29,325 Class A shares at a weighted average price of $32.55.

Were these trades executed under a trading plan for KNSA insider activity?

Yes. The filing states the transactions were effected pursuant to a Rule 10b5-1 plan executed on May 16, 2024.

What post-transaction ownership figures are reported for KNSA?

The Form 4 reports post-transaction beneficial ownership figures of 86,728 and 57,403 Class A shares, and 36,542 derivative securities.

At what price were the sold shares executed for KNSA?

The sale was executed in multiple trades through a broker-dealer at prices ranging between $32.13 and $33.08, with a reported weighted average sale price of $32.55.

Is there confirmation the option exercised by the KNSA insider was vested?

Yes. The filing explicitly states the option is fully vested and exercisable.